SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Incyte (INCY)
An SI Board Since January 1996
Posts SubjectMarks Bans Symbol
3202 131 0 INCY
Emcee:  scaram(o)uche Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2127Although 30% isn't what it used to be with this stock, I'll take it.quidditch-11/21/2005
2126And the stock is up 30%tom pope-11/21/2005
2125Pfizer inks CCR2 license with INCY: investor.incyte.com; NEW YORK & WILMINquidditch-11/21/2005
2124Doc, Extra Pale, thanks. i'll still be here. through the detailed cc notesoftware salesperson-11/2/2005
2123Much appreciation for your contributions, hope you are sticking around SI.Extra Pale-11/2/2005
2122Sales, Let me add my thanks to those of many others for the great work you'Doc Bones-11/2/2005
212111/01/05 cc notes 1. 3rd q review Reverset’s name has to be changed and, in thsoftware salesperson-11/1/2005
2120Human Gene Patents 'Surprisingly High,' A New Study Shows Message 2179Doc Bones-10/13/2005
2119Did the company publish or release data from the phase 1 for INCB3284? TIA.kenhott-10/4/2005
2118I haven't had a chance to listen yet. But I certainly did not expect moving keokalani'nui-9/28/2005
2117reasons for the fda action: (i) post hoc subgroup analysis (ii) # of evaluable software salesperson-9/28/2005
2116advertisement UPDATE 2-U.S. won't OK late-stage trials of Incyte HIV drug WeA.J. Mullen-9/28/2005
2115WILMINGTON, Del.--(BUSINESS WIRE)--Sept. 28, 2005--Incyte Corporation (NASDAQ:INquidditch-9/28/2005
2114Thanks sales. Surely can't partner ccr2 for t2 until after p1b, minimum.keokalani'nui-9/7/2005
2113thomas weisel conference no slides; no presentation; informal q&a re: ccr2software salesperson-9/7/2005
2112New study backs concept behind Glaxo heart drug Mon Sep 5, 2005 10:30 AM ET STOkeokalani'nui-9/6/2005
2111MLNM CCR2inh.<i> CAMBRIDGE, Mass., Aug. 18 /PRNewswire-FirstCall/ -- Millkeokalani'nui-8/18/2005
2110I have the attention span of a dog with two tails but will give the cc a shot. kenhott-8/4/2005
2109kenhott, The CC is still on the website. It is 90 minutes long accompanied by keokalani'nui-8/3/2005
2108Nice notes. Just curious, did INCY see elevated serum amylase levels, other thakenhott-8/3/2005
2107from yahoo: piper jaffray's thomas wei Positive Update From IAS Meeting KEsoftware salesperson-8/2/2005
21068/2/05 cc notes This cc was also a live presentation to the analyst community osoftware salesperson-8/2/2005
2105I don't think Reverset would have been used much with 3TC or FTC anyway. Bumicrocapfun-8/2/2005
2104A rather confusing conference call. A lot of data/ post hoc analysis to absorb. software salesperson-7/26/2005
2103Phase IIb Study Shows Reverset(TM) Has Potent Antiviral Activity in Treatment-Exnigel bates-7/25/2005
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News